Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2007-08-21
2007-08-21
Tran, S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S468000, C424S469000, C424S470000, C424S474000, C424S475000, C424S489000, C424S490000
Reexamination Certificate
active
09831681
ABSTRACT:
Orally administered chromones have been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic urticaria, and irritable bowel syndrome if it is presented such that the respective chromone becomes bioavailable within ten minutes of exposure to an intestinal fluid.
REFERENCES:
patent: 4067992 (1978-01-01), Kingsley et al.
patent: 4232012 (1980-11-01), Orr et al.
patent: 6200602 (2001-03-01), Watts et al.
patent: 9900116 (1999-01-01), None
patent: 0502092 (1992-09-01), None
patent: 1423985 (1976-02-01), None
patent: 1525294 (1978-09-01), None
patent: 1549229 (1979-07-01), None
patent: 1569612 (1980-06-01), None
patent: 1595220 (1981-08-01), None
patent: 2086227 (1982-05-01), None
patent: 2 324 962 (1998-11-01), None
patent: WO85/00015 (1985-01-01), None
patent: WO94/28911 (1994-12-01), None
patent: WO98/51300 (1998-11-01), None
D. Kumar, “Gastric Motor Physiology and Pathophysiology”—The Stomach—Churchill Livingstone, London (1992) pp. 129-142.
L. Businco et al, “Evaluation of the Efficacy of Oral Cromolyn Sodium or an Oligoantigenic Diet in Children with Atopic Dermatitis: A Multicenter Study of 1085 Patients”—J Invest Allerg Clin Immunol—6(s), 103-109 (1996).
A. C. DeGroot et al., “Contact Allergy to Cocamidopropyl Betaine”—Contact Dermititis—33(6), 419-156 (1995).
G.F. Moss et al., “Plasma Levels and Urinary Excretion of Disodium Cromoglycate After Inhalation by Human Volunteers”—Toxicol &Appl Pharm—20, 147-156 (1971).
. Horowitz et al., “Changes in Gastric Emptying Rates with Age”—Clinical Science 67, 213-218 (1984).
Fimmel et al. “Long-Term Ambulatory Gastric pH Monitoring: Validation of a New Method and Effect of H2- Antagonists”—CASTROENTEROL—88, 1842-1851, (1985).
E.J. Prewett, et al., “Twenty-Four Hour Intragastric Acidity and Plasma Gastrin Concentration Profiles in Female and Male Subjects”—Clinical Science—80, 619-624 (1991).
J.R. Malagelada et al., “Measurement of Gastric Functions During Digestion of Ordinary Solid Meals in Man”—GASTROENTEROL—70, 203-210 (1976).
U. Bengtsson et al., “IgE-Positive Duodenal Mast Cells in Patients with Food-Related Diarrhea”—Int Arch Allergy Appl Immunol—95, 86-91 (1991).
L.J. Miller et al., “Postprandial Duodenal Function in Man”—GUT—19, 699-706, (1978).
J-R Malagelada et al., “Quantification of Gastric Solid-Liquid Discrimination During Digestion of Ordinary Meals”—GASTROENTEROL—72, 1264-1267 (1977).
Haugen Law Firm PLLP
Thornton & Ross Limited
Tran S.
LandOfFree
Chromone enteric release formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chromone enteric release formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromone enteric release formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3858129